Tuesday, September 23, 2014
Inquirer Daily News

Daniel Hoffman

A lesson or two from GSK's Chinagate

Monday, July 29, 2013, 6:00 AM
GlaxoSmithKline's (GSK's) Chinagate scandal of the past few weeks provides some belated insight on the China fantasy that pharma has been peddling to investors for much of the last decade. The basic pretense that pharma could somehow offset its wave of patent expirations, its dearth of compelling... Read more

Problems developing effective Alzheimer's therapies

Friday, July 19, 2013, 6:05 AM
Last week Eli Lilly announced that later this year it would start another late-stage (Phase 3) study of its monoclonal antibody, solanezumab, to test whether it can slow the advance of Alzheimer's disease. A pair of solanezumab Phase 3 trials last year failed to show efficacy in patients with mild-to-moderate... Read more

Which side is Pharma on?

Wednesday, July 10, 2013, 6:05 AM
Even as some health care trends slowly work their way to the surface, the mass media remains five years behind reality and has yet to recognize them. Yet the reactions of the world's nations to these trends will determine the nature of global health care in 2020 and beyond. The positions pharma takes... Read more

Nice bonds for conservative investors

Thursday, June 27, 2013, 10:12 AM
A monthly review of Big Cap pharma stocks by Sanford Bernstein, a large fee-analyst company, offers some insights in what it says and what it doesn't say. As with other equity analysts, Bernstein draws a wide distinction between a company's/sector's fundamentals and its value as a stock. Based on... Read more

The reactionary myth that's letting finance managers ruin pharma companies

Wednesday, June 19, 2013, 6:00 AM
Pharma's finance managers have come in for some heavy hits in this space during the past two years. They deserve every swat and then some. CFOs and their henchmen have destroyed Big Pharmas foundation as research-driven, growth companies and have driven off some of its most experienced, capable people... Read more

Pharma as a fading power hitter

Wednesday, June 12, 2013, 6:00 AM
Approximately half the drugs now in clinical development involve an approach known as targeted therapy. Last week's posting discussed some of the problems associated with that strategy. These include increasing the risks of drug development, price gouging, fostering a blind-leading-the-blind phenomenon... Read more

Pharma needs an R&D strategy

Thursday, June 6, 2013, 10:08 AM
Recently a knowledgeable pharma veteran lamented the fact that the industry has not widely adopted what he considers a particularly useful approach to drug development. One company "had it right," he wrote, "when their research model was to study particular pathways and find drugs to affect various... Read more

Organize health care as if it was war

Wednesday, May 29, 2013, 6:00 AM
Does the private control of drug development and health care in general bestow better health and prosperity on Americans? For people in the C-suites, their bluestocking shareholders and some others, it undoubtedly does. For most Americans, it doesn't appear to work so well. Earlier this year the... Read more

Can Pharma handle pricing for value in this country?

Tuesday, May 21, 2013, 10:05 AM
All sectors in the health care business face major turning points within the next three years. This means the pharmaceutical industry and other manufacturers, together with providers such as physicians and hospitals, will operate in a different environment by the end of this decade. The important... Read more

Pharmas made less money but bought their own stock

Monday, May 13, 2013, 9:27 AM
Did anyone in Big Pharma post improved results for the first quarter? Pfizer, Merck, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Sanofi and Novartis (the last two in their pharmaceutical operations) all generated lower sales this past quarter, compared to the same period last year. Some companies... Read more
About this blog

Check Up covers major health events in our region and offers everything from personal health advice to an expert look at health reform. Read about some of our bloggers here.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Also on Philly.com:
Stay Connected